GILD · 8-K · 20260804PR000028

Market Demand Trends

GILEAD SCIENCES, INC. · 2026-08-04 · Importance 64 · Surprise 56

Total product sales excluding Veklury increased 10% year over year to $7.6 billion in the second quarter of 2026. HIV product sales rose 12% to $5.7 billion, driven by higher average realized price and demand. Biktarvy sales increased 7% to $3.8 billion, while Descovy sales increased 48% to $967 million, both reflecting higher demand. Trodelvy sales increased 26% to $457 million on higher demand, and Liver Disease portfolio sales rose 10% to $877 million, primarily due to Livdelzi.